RELAX
Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (RELAX)
| Studienleiter | Prof. Dr. Christoph Röllig |
|---|---|
| EudraCT-Nr. | 2018-003025-28 |
| Studientyp | Phase I / II |
| Indikation | AML |
| ClinicalTrial | NCT04330820 |